Haynes Boone represented Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company pioneering oral drug delivery solutions, in the strategic sale of its subsidiary Oratech Pharma, Inc. to Lifeward Ltd., a revenue-generating medical robotics company. The transaction, which closed on March 25, 2026, strengthens Oramed’s capital position and aligns the company with Lifeward’s expanding footprint in assistive robotics and exoskeleton technologies.
At closing, Lifeward issued 2,256,476 ordinary shares and pre‑funded warrants and 1,296,296 additional warrants to Oramed, and it agreed to provide quarterly revenue‑sharing payments tied to sales of its ReWalk Personal Exoskeleton and related extended warranties.
The Haynes Boone team advising Oramed throughout the transaction was led by Capital Markets and Securities Co-Chair Rick Werner, Mergers and Acquisitions Partner Simin Sun and Capital Markets and Securities Partner Alla Digilova. They were supported by:
- Business Planning and Tax Chair Sam Lichtman
- Finance Partner Mac Henry
- Corporate Associates Lisa Vasek, Cheyenne Karp and Brent Duddles
“Building on our work with Oramed in January, it was great to see the transaction advance to the issuance of warrants,” said Werner. “Our team’s experience and familiarity with company enabled a smooth closing and helped position Oramed for its next phase of growth.”
Haynes Boone's Capital Markets and Securities Practice has played a leading role in numerous IPOs, reverse mergers, acquisitions, follow-on offerings and PIPE financings in recent years across sectors including technology, life sciences, energy and financial services. The firm provides comprehensive advice to clients trading on all major U.S. securities exchanges, over-the-counter markets and all major UK and many international stock markets on a full range of securities transactions and reporting matters.
